TG
NTLA icon

TCW Group’s Intellia Therapeutics NTLA Stock Holding History

TCW Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-84,794
Closed -$2.68M – 380
2023
Q3 		$2.68M Buy
84,794
+31,034
+58% +$1.2M 0.03% 205
2023
Q2 		$2.19M Buy
53,760
+1,209
+2% +$49K 0.02% 230
2023
Q1 		$1.96M Buy
52,551
+32,072
+157% +$1.26M 0.03% 219
2022
Q4 		$715K Buy
+20,479
New +$974K 0.01% 271

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

TCW Group's NTLA Position: Q4 2023 in Review

TCW Group sold out of Intellia Therapeutics (NTLA) in Q4 2023, closing a stake of 84,794 shares — an estimated $2.68M sold.

TCW Group first reported a position in NTLA in Q4 2022 and held it in 4 quarters. The position peaked at $2.68M in Q3 2023. 292 funds tracked by Wall St. Rank hold NTLA as of Q4 2023.

  • TCW Group reported no remaining Intellia Therapeutics position as of Q4 2023 after selling out during the quarter.
  • TCW Group sold 84,794 Intellia Therapeutics shares in Q4 2023, an estimated $2.68M.
  • TCW Group first reported a position in Intellia Therapeutics in Q4 2022 and held it in 4 quarters.
  • TCW Group's Intellia Therapeutics position peaked at $2.68M in Q3 2023.
  • 292 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2023.

Based on TCW Group's 13F filing for Q4 2023, filed 9 Feb 2024.